Literature DB >> 16580631

Protection against avian influenza H9N2 virus challenge by immunization with hemagglutinin- or neuraminidase-expressing DNA in BALB/c mice.

Meizhen Qiu1, Fang Fang, Yan Chen, Hualin Wang, Quanjiao Chen, Haiyan Chang, Fuyan Wang, Hanzhong Wang, Ran Zhang, Ze Chen.   

Abstract

Avian influenza viruses of H9N2 subtype are widely spread in avian species. The viruses have recently been transmitted to mammalian species, including humans, accelerating the efforts to devise protective strategies against them. In this study, an avian influenza H9N2 virus strain (A/Chicken/Jiangsu/7/2002), isolated in Jiangsu Province, China, was used to infect BALB/c mice for adaptation. After five lung-to-lung passages, the virus was stably proliferated in a large quantity in the murine lung and caused the deaths of mice. In addition, we explored the protection induced by H9N2 virus hemagglutinin (HA)- and neuraminidase (NA)-expressing DNAs in BALB/c mice. Female BALB/c mice aged 6-8 weeks were immunized once or twice at a 3-week interval with HA-DNA and NA-DNA by electroporation, respectively, each at a dose of 3, 10 or 30microg. The mice were challenged with a lethal dose (40x LD(50)) of influenza H9N2 virus four weeks after immunization once or one week after immunization twice. The protections of DNA vaccines were evaluated by the serum antibody titers, residual lung virus titers, and survival rates of the mice. The result showed that immunization once with not less than 10microg or twice with 3microg HA-DNA or NA-DNA provided effective protection against homologous avian influenza H9N2 virus.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16580631     DOI: 10.1016/j.bbrc.2006.03.088

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  24 in total

1.  Biological and protective properties of immune sera directed to the influenza virus neuraminidase.

Authors:  Stefan J Halbherr; Thomas H Ludersdorfer; Meret Ricklin; Samira Locher; Marianne Berger Rentsch; Artur Summerfield; Gert Zimmer
Journal:  J Virol       Date:  2014-11-12       Impact factor: 5.103

2.  Novel linear DNA vaccines induce protective immune responses against lethal infection with influenza virus type A/H5N1.

Authors:  Frédéric Kendirgi; Nadezda E Yun; Nathaniel S Linde; Michele A Zacks; Jeanon N Smith; Jennifer K Smith; Harilyn McMicken; Yin Chen; Slobodan Paessler
Journal:  Hum Vaccin       Date:  2008-11-21

Review 3.  Contribution of antibody production against neuraminidase to the protection afforded by influenza vaccines.

Authors:  Glendie Marcelin; Matthew R Sandbulte; Richard J Webby
Journal:  Rev Med Virol       Date:  2012-03-22       Impact factor: 6.989

4.  Electroporation-mediated gene delivery.

Authors:  Jennifer L Young; David A Dean
Journal:  Adv Genet       Date:  2014-12-11       Impact factor: 1.944

5.  Neuraminidase expressing virus-like particle vaccine provides effective cross protection against influenza virus.

Authors:  Ki-Hye Kim; Young-Tae Lee; Soojin Park; Yu-Jin Jung; Youri Lee; Eun-Ju Ko; Yu-Jin Kim; Xuguang Li; Sang-Moo Kang
Journal:  Virology       Date:  2019-07-08       Impact factor: 3.616

6.  The nucleoprotein of newly emerged H7N9 influenza A virus harbors a unique motif conferring resistance to antiviral human MxA.

Authors:  David Riegger; Rong Hai; Dominik Dornfeld; Benjamin Mänz; Victor Leyva-Grado; Maria T Sánchez-Aparicio; Randy A Albrecht; Peter Palese; Otto Haller; Martin Schwemmle; Adolfo García-Sastre; Georg Kochs; Mirco Schmolke
Journal:  J Virol       Date:  2014-12-10       Impact factor: 5.103

7.  Influenza M1 VLPs containing neuraminidase induce heterosubtypic cross-protection.

Authors:  Fu-Shi Quan; Min-Chul Kim; Byeong-Jae Lee; Jae-Min Song; Richard W Compans; Sang-Moo Kang
Journal:  Virology       Date:  2012-06-02       Impact factor: 3.616

Review 8.  Influenza vaccines.

Authors:  A H Ellebedy; R J Webby
Journal:  Vaccine       Date:  2009-11-05       Impact factor: 3.641

Review 9.  Virus-like particles as universal influenza vaccines.

Authors:  Sang-Moo Kang; Min-Chul Kim; Richard W Compans
Journal:  Expert Rev Vaccines       Date:  2012-08       Impact factor: 5.217

10.  Comparing the ability of a series of viral protein-expressing plasmid DNAs to protect against H5N1 influenza virus.

Authors:  Quanjiao Chen; Haimen Kuang; Huadong Wang; Fang Fang; Zhongdong Yang; Zhiping Zhang; Xianen Zhang; Ze Chen
Journal:  Virus Genes       Date:  2008-12-10       Impact factor: 2.332

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.